Earnings results for Exelixis (NASDAQ:EXEL)
Cimarex Energy Co is expected* to report earnings on 08/05/2021 before market open. The report will be for the fiscal Quarter ending Jun 2021. According to Zacks Investment Research, based on 24 analysts’ forecasts, the consensus EPS forecast for the quarter is $1.8599999999999999. The reported EPS for the same quarter last year was $-0.51.
Exelixis last issued its earnings results on August 5th, 2021. The biotechnology company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.25. The company earned $385.18 million during the quarter, compared to analyst estimates of $296.31 million. Exelixis has generated $0.35 earnings per share over the last year ($0.29 diluted earnings per share) and currently has a price-to-earnings ratio of 74.2. Earnings for Exelixis are expected to grow by 22.86% in the coming year, from $0.70 to $0.86 per share. Exelixis has confirmed that its next quarterly earnings report will be published on Tuesday, November 2nd, 2021. Exelixis will be holding an earnings conference call on Tuesday, November 2nd at 5:00 PM Eastern. Interested parties can or dial in at 404-537-3406 with passcode “9563879”.
Analyst Opinion on Exelixis (NASDAQ:EXEL)
According to the issued ratings of 10 analysts in the last year, the consensus rating for Exelixis stock is Buy based on the current 1 hold rating and 9 buy ratings for EXEL. The average twelve-month price target for Exelixis is $34.78 with a high price target of $65.00 and a low price target of $26.00.
Exelixis has received a consensus rating of Buy. The company’s average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings. According to analysts’ consensus price target of $34.78, Exelixis has a forecasted upside of 61.7% from its current price of $21.51. Exelixis has only been the subject of 3 research reports in the past 90 days.
Dividend Strength: Exelixis (NASDAQ:EXEL)
Exelixis does not currently pay a dividend. Exelixis does not have a long track record of dividend growth.
Insiders buying/selling: Exelixis (NASDAQ:EXEL)
In the past three months, Exelixis insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,564,400.00 in company stock. Only 3.30% of the stock of Exelixis is held by insiders. 83.76% of the stock of Exelixis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Exelixis (NASDAQ:EXEL
Earnings for Exelixis are expected to grow by 24.64% in the coming year, from $0.69 to $0.86 per share. The P/E ratio of Exelixis is 74.17, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.98. The P/E ratio of Exelixis is 74.17, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 31.32. Exelixis has a PEG Ratio of 0.66. PEG Ratios below 1 indicate that a company could be undervalued. Exelixis has a P/B Ratio of 3.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here